In the base-case analyses, a monetary threshold of €20,0000 is used [ 40].
For the base case analyses, the cost of a false negative (pre-diabetes or diabetes that was undetected) was evaluated as 10% of the projected marginal 3-year medical costs for that condition, assuming that marginal costs could be decreased by appropriate management, as they were in the Diabetes Prevention Program DPPP) (16, 17).
Base case analyses revealed that agomelatine is a dominant therapy for MDD relative to escitalopram, fluoxetine and sertraline, and it appeared to be cost-effective compared to venlafaxine (ICER: €547/QALY).
For the base case analyses, costs, and health benefits were discounted at a 3.5% rate per annum.
In accordance with the World Health Organization's guide to cost-effectiveness analyses, costs and QALYs were discounted at 3% annually for the base case analyses, but further sensitivity analyses were also conducted using a 6% annual discount rate for costs and a 0% annual discount rate for QALYs [ 30, 31].
19 Base case analyses were performed with Markov cohort simulation with transitions modelled on an annual basis, though we used first order Monte Carlo simulation to determine the incidence of end stage renal disease over time.
The base case analyses assumed 80% to 96% coverage depending on age in infants and children, 75% in adolescents, 40% with routine adult vaccination, and 65% in parents of newborns [25].
